Bradycardic syncope in 2 patients who recently began gatifloxacin treatment.
Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone approved by the United States Food and Drug Administration in December 1999. Few side effects of this new antibiotic have been reported, and there are no previous case reports of bradyarrhythmias. We report 2 cases of syncope due to bradycardia in patients who recently began treatment with gatifloxacin.
Nicholson
W J
WJ
Department of Medicine, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island 02903, USA.
Buxton
A E
AE
Tammaro
D
D
D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced*; D005260:Female; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006801:Humans; D013575:Syncope / Q000139:chemically induced*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin